You would be hard pressed to find any BioTech with a Market Cap under $ 100 m that has completed Phase II trials. That would bring us up by $35 m. Especially if the PR and Investor relations make a song and dance about it. Revenue from Treatment should begin in November or December, would be nice to know the numbers now, if we are treating patients in 6 months, how much will the treatment be? what margin are LCT looking at? Numbers time, Business time, Returns time, Its been a decade of shareholder support $ 68 million to date, so time to explain the Payback....being so close to commercialisation.
Completion Day for Group 3 Phase II?, page-6
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $7.007K | 1.008M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 2864983 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2187552 | 7 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |